No Evidence of Metabolomic Disruptions From Real‐World Intakes of Aspartame or Saccharin: The Coronary Artery Risk Development in Young Adults Study
Journal of Diabetes · 2025
DOI: 10.1111/1753-0407.70138 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Diabetes, 2025. Verfasst von Brian T Steffen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Computational Health Sciences, Department of Surgery, University of Minnesota School of Medicine, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Aspartame, Saccharin, Metabolomics, Sweetening Agents. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute (NHLBI), Northwestern University.
Abstract (Originalsprache)
Background
Artificial sweeteners have become ubiquitous additives in the food supply, and yet the safety of their regular consumption remains controversial. The present study examined whether intakes of aspartame or saccharin are related to aberrations in the plasma metabolome indicating disruptions in metabolism.
Methods
A cohort of 2160 male and female participants, mean age 32.1 years, was included in the analysis. Liquid chromatography and mass‐spectrometry assessed 549 unique plasma metabolites. Diet was assessed using a validated questionnaire that allowed for estimation of aspartame and saccharin intakes. A generalized linear regression model evaluated associations of saccharin or aspartame intake with plasma metabolites with adjustment for potential confounders and multiple comparisons. Multiple sensitivity analyses and propensity score matching were conducted.
Results
Heavy aspartame intake (≥ 5 servings/day) was associated with plasma levels (per SD) of saccharin ( β = 0.90; q = 9.0E‐36), myo‐inositol ( β = 0.27; q = 3.7E‐04), caffeine ( β = 0.31; q = 4.1E‐04), and five metabolites of caffeine including 1,7‐dimethyluric acid ( β = 0.37; q = 7.1E‐06), 1‐methylurate ( β = 0.36; q = 7.1E‐06), 5‐acetylamino‐6‐amino‐3‐methyluracil ( β = 0.38; q = 3.2E‐6), theophylline ( β = 0.36; q = 9.1E‐06), and 1‐methylxanthine ( β = 0.32; q = 2.0E‐03). Saccharin intake was associated with plasma levels of saccharin alone ( β = 0.29; q = 1.8E‐10). No associations with sugars, carbohydrates, lipids, amino acids, or other metabolites that would suggest metabolic perturbations were observed with either artificial sweetener; sensitivity analyses supported these findings.
Conclusions
In the largest metabolomics study to date, no link was found between metabolic disruptions and either aspartame or saccharin intake. We cannot exclude the possibility that more extreme intakes may be related to metabolic disruptions among consumers of artificial sweeteners.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Computational Health Sciences, Department of Surgery, University of Minnesota School of Medicine, Minneapolis, Minnesota, USA.
- Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA.
- Department of Food Science and Nutrition, University of Minnesota, St. Paul, Minnesota, USA.
- Departments of Medicine and Radiology, University of Michigan, Ann Arbor, Michigan, USA.
- Nutrition Division, Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University in Chicago, Chicago, Illinois, USA.
- Department of Radiology and Vanderbilt Translational and Clinical Cardiovascular Research Center (VTRACC), Vanderbilt University Medical Center, Nashville, Tennessee, USA.
ORCID-Profile: Brian T Steffen
Förderung
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute (NHLBI)
- Northwestern University
- University of Minnesota
Zitieren
APA
Steffen, B. T., Lusczek, E. R., Jacobs, D. R., Chen, C., Murthy, V. L., Van Horn, L., Terry, J. G., Carr, J. J., & Steffen, L. M. (2025). No Evidence of Metabolomic Disruptions From Real‐World Intakes of Aspartame or Saccharin: The Coronary Artery Risk Development in Young Adults Study. Journal of Diabetes. https://doi.org/10.1111/1753-0407.70138
Vancouver
Steffen BT, Lusczek ER, Jacobs DR, Chen C, Murthy VL, Van Horn L, et al. No Evidence of Metabolomic Disruptions From Real‐World Intakes of Aspartame or Saccharin: The Coronary Artery Risk Development in Young Adults Study. Journal of Diabetes. 2025. doi:10.1111/1753-0407.70138
BibTeX
@article{Steffen2025,
author = {Steffen, Brian T and Lusczek, Elizabeth R and Jacobs, David R and Chen, Chi and Murthy, Venkatesh L and Van Horn, Linda and Terry, James G and Carr, John Jeffrey and Steffen, Lyn M},
title = {No Evidence of Metabolomic Disruptions From Real‐World Intakes of Aspartame or Saccharin: The Coronary Artery Risk Development in Young Adults Study},
journal = {Journal of Diabetes},
year = {2025},
doi = {10.1111/1753-0407.70138}
}
EUVIMED